![]() |
市场调查报告书
商品编码
1679225
栓剂包装市场预测至 2030 年:按包装类型、材料、应用和地区进行的全球分析Suppository Packaging Market Forecasts to 2030 - Global Analysis By Packaging Type (Blister Packaging, Strip Packaging and Form-Fill-Seal (FFS) Packaging), Material, Application and By Geography |
根据 Stratistics MRC 的数据,2024 年全球栓剂包装市场价值为 4.2304 亿美元,预计到 2030 年将达到 6.602 亿美元,预测期内的复合年增长率为 7.7%。
为保护、储存和管理栓剂而设计的专门包装选项称为栓剂包装。这些包装可防止污染,同时确保产品的完整性、卫生规范和管理的便利性。为了维持产品有效性,栓剂包装必须提供防潮、防光和防温度变化的阻隔保护。它作为阴道和直肠栓剂广泛应用于製药和医疗领域。
医疗支出增加
全球医疗保健支出的增加是栓剂包装市场发展的主要驱动力。随着政府和个人向医疗保健分配更多的资源,对包括栓剂在内的药品的投资正在增加。这些资金承诺促进了先进药物输送系统的开发和采用,从而产生了对高品质包装解决方案的需求。人口老化,特别是发达地区的人口老化,正在加速这一趋势,因为老年人口需要更多的药物。
严格的监管核准
FDA 等监管机构对药品包装制定了严格的标准,以确保产品的安全性、稳定性和有效性。这些法规要求进行大量的测试、记录和合规程序,从而延长了产品开发时间并增加了製造商的成本。此外,由于不同地区的法规不尽相同,迫使企业调整其包装解决方案以符合不同市场的不同标准。这些挑战尤其影响中小型製造商,他们努力获得在复杂的监管环境中生存所需的资金和技术资源。
包装材料创新
生物分解性和环保材料的开发响应了日益增长的环境问题,并与製药业的永续性一致。结合物联网功能的智慧包装技术能够在储存和运输过程中实现状况监控,提高产品安全性和患者依从性。先进材料具有更好的阻隔性能,可抵御湿气、光线和温度变化,从而延长产品的保质期并保持功效。此外,易于管理的材料可以提高患者的舒适度。这些创新有可能透过更有效率的製造流程和减少材料废弃物来节省成本。
认知和接受度有限
儘管该疗法具有治疗作用,但由于文化禁忌以及患者对直肠和阴道给药方式的不适,许多地区拒绝采用该疗法。医疗保健提供者可能还会犹豫是否开立栓剂,因为他们认为患者不喜欢它们,这限制了市场渗透。此外,缺乏关于正确的给药技术和栓剂与口服药物相比的益处的教育也阻碍了市场的成长。这项挑战在保守社会和新兴市场尤其明显,因为这些社会更倾向于采用替代管理方法。
COVID-19 疫情最初透过供应链挑战和製造限制扰乱了栓剂包装市场。然而,这场危机随后加速了某些市场趋势,例如人们更加关注药品包装的完整性和无菌性。疫情提高了人们对药品安全性和稳定性的认识,推动了对高品质包装解决方案的需求。此外,医疗产业在疫情期间迅速适应新挑战,刺激了药品包装的创新,包括增加保护功能的栓剂包装设计和可安全在家中使用的易于使用的给药方法。
预计预测期内铝/聚乙烯 (Alu/PE) 部分将成为最大的部分。
预计铝/聚乙烯 (Alu/PE) 材料将在预测期内占据最大的市场占有率,因为它兼具优异的阻隔性和功能性。这种包装材料提供了卓越的防潮、防光、防氧和防污染保护,确保了栓剂在使用前的稳定性和有效性。这种材料的化学惰性可防止与封装药物发生相互作用,其物理耐用性可在处理和运输过程中保护精密栓剂,因此受到全球製药商的青睐。
预计预测期内尿道部分将以最高的复合年增长率成长。
由于泌尿系统疾病盛行率的不断上升和靶向药物输送系统的进步,预计尿道部分将在预测期内呈现最高的成长率。对于需要局部治疗的情况,尿道栓剂可以提供直接有效的药物给药,与口服药物相比,全身副作用较少。药物传递技术的发展提高了尿道栓剂的有效性和舒适度,从而被医疗保健专业人士越来越多地采用。此外,人口老化和泌尿器官系统疾病发病率高也进一步推动了对这些专门治疗方案的需求。
预计预测期内欧洲地区将占据最大的市场占有率。这是因为与其他地区相比,这里的製药业更加成熟,医疗保健基础设施更加先进,并且对栓剂剂型的文化接受度更高。欧洲国家长期以来一直使用栓剂作为处方药和非处方药,因此对高品质的包装解决方案有着稳定的需求。该地区对药品包装的严格监管标准也推动了采用优质包装材料,以确保产品的稳定性和安全性。此外,欧洲人口老化和医疗支出的增加进一步促进了欧洲栓剂包装市场的持续成长。
在预测期内,由于医疗保健基础设施的扩大、製药製造活动的增加以及印度和中国等国家的医疗保健支出的增加,预计亚太地区将呈现最高的复合年增长率。该地区不断增长的人口和不断改善的医疗服务创造了巨大的市场机会。此外,人们对先进药物传递系统的认识不断提高,以及医疗环境中对栓剂剂型的逐渐接受,进一步推动了全部区域市场的成长。
According to Stratistics MRC, the Global Suppository Packaging Market is accounted for $423.04 million in 2024 and is expected to reach $660.20 million by 2030 growing at a CAGR of 7.7% during the forecast period. Specialized packaging options made to safeguard, store, and administer suppository drugs are referred to as suppository packaging. These packaging's guard against contamination while guaranteeing product integrity, hygienic practices, and convenience of administration. To preserve product efficacy, suppository packaging needs to offer barrier protection against moisture, light, and temperature changes. It is extensively utilized for vaginal and rectal suppositories in the pharmaceutical and medical sectors.
Rising healthcare expenditure
The increasing healthcare expenditure globally is a significant driver for the suppository packaging market. As governments and individuals allocate more resources to healthcare, there is greater investment in pharmaceutical products, including suppositories. This financial commitment enables the development and adoption of advanced drug delivery systems, creating demand for high-quality packaging solutions. The aging population, particularly in developed regions, further accelerates this trend as older demographics require more medications.
Stringent regulatory approvals
Regulatory bodies like the FDA impose rigorous standards for pharmaceutical packaging to ensure product safety, stability, and efficacy. These regulations necessitate extensive testing, documentation, and compliance procedures, which extend product development timelines and increase costs for manufacturers. Additionally, regulations vary across regions, requiring companies to adapt their packaging solutions to meet different standards in various markets. These challenges particularly affect smaller manufacturers who may struggle with the financial and technical resources needed to navigate complex regulatory landscapes.
Innovations in packaging materials
The development of biodegradable and eco-friendly materials addresses growing environmental concerns and aligns with sustainability initiatives in the pharmaceutical industry. Smart packaging technologies incorporating IoT features enable condition monitoring during storage and transit, enhancing product safety and patient compliance. Advanced materials with improved barrier properties against moisture, light, and temperature fluctuations extend product shelf life and maintain efficacy. Additionally, materials that facilitate administration improve patient experience. These innovations potentially reduce costs through more efficient manufacturing processes and reduced material waste.
Limited awareness and acceptance
Despite their therapeutic advantages, cultural taboos and patient discomfort regarding rectal or vaginal administration methods create resistance to adoption in many regions. Healthcare providers may also hesitate to prescribe suppositories due to perceived patient reluctance, limiting market penetration. Additionally, the lack of education about proper administration techniques and benefits of suppositories compared to oral medications further constrains market growth. This challenge is particularly pronounced in conservative societies and emerging markets where alternative delivery methods are preferred.
The COVID-19 pandemic initially disrupted the suppository packaging market through supply chain challenges and manufacturing restrictions. However, the crisis subsequently accelerated certain market trends, including increased focus on pharmaceutical packaging integrity and sterility. The pandemic heightened awareness about medication safety and stability, driving demand for high-quality packaging solutions. Additionally, the healthcare industry's rapid adaptation to new challenges during the pandemic fostered innovation in pharmaceutical packaging, including suppository packaging designs with enhanced protective features and user-friendly administration methods that could be used safely at home.
The aluminum/PE (Alu/PE) segment is expected to be the largest during the forecast period
The aluminum/PE (Alu/PE) segment is expected to account for the largest market share during the forecast period due to its superior combination of barrier properties and functionality. This packaging material provides excellent protection against moisture, light, oxygen, and contaminants, ensuring the stability and efficacy of suppository formulations until use. The material's chemical inertness prevents interaction with the enclosed medication, while its physical durability protects delicate suppositories during handling and transportation, making it the preferred choice for pharmaceutical manufacturers worldwide.
The urethral segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the urethral segment is predicted to witness the highest growth rate due to the increasing prevalence of urological conditions and advancements in targeted drug delivery systems. Urethral suppositories provide direct and efficient medication administration for conditions requiring localized treatment, reducing systemic side effects compared to oral medications. Developments in drug delivery technologies have improved the efficacy and comfort of urethral suppositories, driving their adoption among healthcare professionals. Additionally, the growing aging population, who experience higher rates of urological issues, further fuels demand for these specialized treatment options.
During the forecast period, the Europe region is expected to hold the largest market share owing to a well-established pharmaceutical industry, advanced healthcare infrastructure, and greater cultural acceptance of suppository dosage forms compared to other regions. European countries have long-standing traditions of suppository use in both prescription and over-the-counter medications, creating a stable demand for high-quality packaging solutions. The region's stringent regulatory standards for pharmaceutical packaging also drive the adoption of premium packaging materials that ensure product stability and safety. Additionally, Europe's aging population and increasing healthcare expenditure further contribute to the sustained growth of the suppository packaging market across the continent.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by expanding healthcare infrastructure, increasing pharmaceutical manufacturing activities, and rising healthcare expenditure across countries like India and China. The region's large and growing population, coupled with improving access to healthcare services, creates substantial market opportunities. Additionally, increasing awareness about advanced drug delivery systems and the gradual acceptance of suppository dosage forms in medical practice are further accelerating market growth throughout the region.
Key players in the market
Some of the key players in Suppository Packaging Market include NextPharma Technologies, CordenPharma, Recipharm AB, Valmatic S.R.L., Sarong S.p.A., Key International, HySum Europe GmbH, FAMAR Health Care Services, Hudi Pharma HQ, Adragos Pharma, LGM Pharma, Aluberg s.p.a., Delpharm, Unither, Trefoil Packaging Pvt Ltd and Gerresheimer AG.
In October 2022, CordenPharma Launches Oral Solid Dose GMP Manufacturing for Clinical Trial Development. Because Oral Solid Dose (OSD) capabilities are in high demand, CordenPharma made the strategic decision to enhance our offering with an investment of €10 million into the design and installation of a new GMP Clinical Trial Development (CTD) facility located in CordenPharma Plankstadt (DE). The installment of the new CTD facility is a response to our customers' demands and the recognition of gaps in scale and technologies.
In October 2022, Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated technology. The low-volume blow-fill-seal (BFS) process has a throughput speed of 2,000 doses per hour and can be easily adapted for a range of different product types and dosage designs, Recipharm said.